Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · IEX Real-Time Price · USD
6.89
+0.07 (1.03%)
At close: Jul 19, 2024, 4:00 PM
6.99
+0.10 (1.45%)
Pre-market: Jul 22, 2024, 7:44 AM EDT

Verve Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Revenue
16.0511.761.94000
Revenue Growth (YoY)
379.79%505.77%----
Gross Profit
16.0511.761.94000
Selling, General & Admin
51.5549.9437.5318.875.262.5
Research & Development
186.21184.95130.168.235.3711.14
Operating Expenses
237.76234.88167.6387.0740.6313.64
Operating Income
-221.71-223.12-165.69-87.07-40.63-13.64
Other Expense / Income
-25.26-23.33-8.3533.255.085.66
Pretax Income
-196.45-199.79-157.33-120.31-45.7-19.3
Income Tax
0.380.280.05000
Net Income
-196.83-200.07-157.39-120.31-45.7-19.3
Shares Outstanding (Basic)
8364542721
Shares Outstanding (Diluted)
8364542721
Shares Change
34.55%18.79%101.04%1094.26%76.18%-
EPS (Basic)
-2.87-3.12-2.91-4.48-20.31-15.11
EPS (Diluted)
-2.87-3.12-2.91-4.48-20.31-15.11
Free Cash Flow
-149.88-158.83-135.56-82.24-38.69-9.3
Free Cash Flow Per Share
-1.80-2.48-2.51-3.06-17.19-7.28
Gross Margin
100.00%100.00%100.00%---
Operating Margin
-1381.45%-1897.64%-8536.17%---
Profit Margin
-1226.43%-1701.55%-8108.55%---
Free Cash Flow Margin
-933.87%-1350.84%-6984.23%---
EBITDA
-183.56-187.55-150.62-116.94-44.38-19.19
EBITDA Margin
-1143.75%-1595.05%-7760.07%---
Depreciation & Amortization
12.8912.256.713.381.330.11
EBIT
-196.45-199.79-157.33-120.31-45.7-19.3
EBIT Margin
-1224.05%-1699.21%-8105.82%---
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).